menu
    • menu
    [{"orgOrder":0,"company":"Convergent Therapeutics","sponsor":"Ionetix","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2022","type":"Agreement","leadProduct":"177-Lu PSMA-I&T","moa":"||PSMA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Convergent Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Convergent Therapeutics \/ Ionetix","highestDevelopmentStatusID":"7","companyTruncated":"Convergent Therapeutics \/ Ionetix"},{"orgOrder":0,"company":"Convergent Therapeutics","sponsor":"OrbiMed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2023","type":"Series A Financing","leadProduct":"225-Ac Rosopatamab Tetraxetan","moa":"PSMA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Convergent Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Convergent Therapeutics \/ OrbiMed","highestDevelopmentStatusID":"7","companyTruncated":"Convergent Therapeutics \/ OrbiMed"},{"orgOrder":0,"company":"Convergent Therapeutics","sponsor":"NorthStar Medical Radioisotopes","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2022","type":"Agreement","leadProduct":"225-Ac Rosopatamab Tetraxetan","moa":"PSMA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Convergent Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Convergent Therapeutics \/ NorthStar Medical Radioisotopes","highestDevelopmentStatusID":"7","companyTruncated":"Convergent Therapeutics \/ NorthStar Medical Radioisotopes"},{"orgOrder":0,"company":"Convergent Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2024","type":"Inapplicable","leadProduct":"225-Ac Rosopatamab Tetraxetan","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Convergent Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Convergent Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Convergent Therapeutics \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Convergent Therapeutics

    Menu

    Convergent Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Convergent Therapeutics

                            U.S.A arrow
                            Interphex
                            Not Confirmed

                            Convergent Therapeutics

                            U.S.A arrow
                            Interphex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 225-Ac Rosopatamab Tetraxetan

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Convergent Announces First Patient Treated in Phase II Trial with Lead Candidate

                            Details : CONV01-α (Ac-225 rosopatamab tetraxetan), alpha emitting radiolabelled antibody, being deve;opment for the treatment of PSMA PET-positive metastatic castration resistant prostate cancer.

                            Product Name : CONV01-alpha

                            Product Type : Radiolabelled Compounds

                            Upfront Cash : Inapplicable

                            September 24, 2024

                            Lead Product(s) : 225-Ac Rosopatamab Tetraxetan

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Convergent Therapeutics

                            U.S.A arrow
                            Interphex
                            Not Confirmed

                            Convergent Therapeutics

                            U.S.A arrow
                            Interphex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 225-Ac Rosopatamab Tetraxetan

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : OrbiMed

                            Deal Size : $90.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Convergent Therapeutics Announces $90 Million Series A Financing to Advance the Clinical Development of Radiop...

                            Details : The financing will advance the clinical development of radiopharmaceuticals for the treatment of prostate cancer and other solid tumors, including its lead program with CONV01-α (actinium-J591), a monoclonal antibody conjugated to actinium-225, for adva...

                            Product Name : CONV01-alpha

                            Product Type : Radiolabelled Compounds

                            Upfront Cash : Undisclosed

                            March 05, 2023

                            Lead Product(s) : 225-Ac Rosopatamab Tetraxetan

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : OrbiMed

                            Deal Size : $90.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Convergent Therapeutics

                            U.S.A arrow
                            Interphex
                            Not Confirmed

                            Convergent Therapeutics

                            U.S.A arrow
                            Interphex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 225-Ac Rosopatamab Tetraxetan

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : NorthStar Medical Radioisotopes

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            NorthStar Medical Radioisotopes and Convergent Therapeutics Announce Supply Agreement for Therapeutic Radioiso...

                            Details : Under terms of the agreement, NorthStar will provide Convergent with its, high purity non-carrier-added Ac-225. Convergent will use NorthStar’s Ac-225 to radiolabel its lead asset, CONV01-α, a prostate-specific membrane antigen targeted monoclonal ant...

                            Product Name : CONV01-alpha

                            Product Type : Radiolabelled Compounds

                            Upfront Cash : Undisclosed

                            September 03, 2022

                            Lead Product(s) : 225-Ac Rosopatamab Tetraxetan

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : NorthStar Medical Radioisotopes

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Convergent Therapeutics

                            U.S.A arrow
                            Interphex
                            Not Confirmed

                            Convergent Therapeutics

                            U.S.A arrow
                            Interphex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 225-Ac Rosopatamab Tetraxetan,177-Lu PSMA-I&T

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Ionetix

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Convergent Therapeutics and IONETIX Announce Supply Agreement for Therapeutic Radioisotope Actinium-225 (Ac-22...

                            Details : The agreement will support Convergent's pipeline of next-generation radiotherapies including its lead asset, CONV01-α (225Ac−Rosopatamab), a prostate-specific membrane antigen (PSMA)-targeted monoclonal antibody linked to Ac-225.

                            Product Name : CONV01-alpha

                            Product Type : Radiolabelled Compounds

                            Upfront Cash : Undisclosed

                            May 25, 2022

                            Lead Product(s) : 225-Ac Rosopatamab Tetraxetan,177-Lu PSMA-I&T

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Ionetix

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth